Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Janssen-Cilag Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (144)
Cancellation by sponsor (48)
Australian Public Assessment Report (AusPAR) (37)
Prescription medicine registration (30)
Designation or determination (6)
Prescription medicine decision summary (5)
Prescription medicine evaluation (2)

Date

2026 (12)
2025 (22)
2024 (16)
2023 (16)
2022 (11)
2021 (15)
2020 (25)
2019 (7)
2018 (9)
2017 (19)
2016 (19)
2015 (7)
2014 (10)
2013 (5)
2012 (5)
2011 (4)
2010 (19)
2009 (6)
2008 (2)
2007 (4)
2006 (3)
2005 (5)
2003 (6)
2002 (2)
2000 (9)
1998 (9)
1996 (1)
1994 (1)
1993 (3)

Search

Sponsor content

272 result(s) found, displaying 151 to 160

IMBRUVICA ibrutinib 140 mg capsule bottle (228499)

20 April 2015

ARTG

Australian Register of Therapeutic Goods (ARTG) information for IMBRUVICA ibrutinib 140 mg capsule bottle.
ERLYAND, JANSSEN APALUTAMIDE (Janssen-Cilag Pty Ltd)

4 July 2018

Prescription medicine registration

Active ingredients: apalutamide.
JANSSEN GUSELKUMAB, TREMFYA (Janssen-Cilag Pty Ltd)

9 March 2018

Prescription medicine registration

Active ingredients: guselkumab.
Notice for apalutamide (Janssen-Cilag Pty Ltd)

17 January 2018

Designation or determination

Priority review
PROMINAD canagliflozin (as hemihydrate)100 mg film-coated tablet blister pack Cancelled under s30(1)(c)

14 December 2017

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
INVOKANA canagliflozin (as hemihydrate) 300 mg film-coated tablet blister pack Cancelled under s30(1)(c)

14 December 2017

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
PROMINAD canagliflozin (as hemihydrate) 300 mg film-coated tablet blister pack Cancelled under s30(1)(c)

14 December 2017

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
INVOKANA canagliflozin (as hemihydrate)100 mg film-coated tablet blister pack Cancelled under s30(1)(c)

14 December 2017

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
AusPAR: Paliperidone palmitate

10 November 2017

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Paliperidone palmitate
AusPAR: Ustekinumab

6 November 2017

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Ustekinumab

Pages

First page
Previous page
…
Page 12
Page 13
Page 14
Page 15
Current page 16
Page 17
Page 18
Page 19
Page 20
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.